Aim. To study the prevalence of various C807T polymorphism variants of the ITGA2 gene and to analyze the association of this polymorphism with platelet aggregation activity in hypertensive patients. Methods. 47 patients with arterial hypertension treated at the Clinical Cardiology Dispensary (Perm) were included in the study. Genotyping of C807T polymorphism (rs 1126643) was carried out by the method of polymerase chain reaction with the subsequent identification of the single nucleotide polymorphic variant of ITGA2 gene by the method of allele-specific polymerase chain reaction. Platelet aggregation activity was investigated by the impedance method using TRAP-6 reagent as an inducer of aggregation. Results. The prevalence of C/C, C/T, T/T genotypes of ITGA2 gene among hypertensive patients was 18 (38.3%), 23 (48.9%) and 6 (12.8%), respectively. A comparative analysis of platelet aggregation activity with TRAP-6 reagent revealed statistically significant differences between the groups of patients carrying different genotypes [103.5 (67.0; 121.0) AU in homozygotes –807CC versus 52.5 (48; 83) AU in homozygotes –807TT, p=0.045]. In the group of patients with reduced platelet aggregation activity (TRAP-test less than 94 AU), the carriage of the unfavorable T allele prevailed in comparison with the group of patients with its normal level (OR=3.81, 95% CI 1.38–10.54; p=0.008). In patients of this group, there was a significant increase in the frequency of occurrence of heterozygotes –807CT (OR=4.75, 95% CI 1.24–18.19; p=0.009), as well as an increase in the frequency of occurrence of homozygotes for the variant allele -807TT (OR=2.88, 95% CI 0.31–27.07; p=0.009) compared with the group of patients with a normal level of aggregation. Conclusion. The prevalence of C/C, C/T, T/T genotypes of ITGA2 gene among patients with arterial hypertension is comparable to the data of European researchers: carriers of T allele of ITGA2 gene may have a higher risk of developing cardiovascular events; the molecular mechanism of the relationship of reduced platelet aggregation activity and carriage of the unfavorable T allele of ITGA2 gene requires further studies.
Comorbidity of arterial hypertension (AH) and gastroesophageal reflux disease (GERD) is widely spread (from 20.6 % to 29 %); despite that fact, risk factors that can cause AH in patients suffering from GERD have still not been examined completely. Experts are discussing a role played by anti-inflammation cytokine of tumor necrosis factor alpha (TNF) both in AH occurrence and GERD pathogenesis as it is its activity that is to a great extent determined by a patient having certain alleles of tumor necrosis factor (TNF) gene. Therefore, it seems vital to study TNF gene G308A polymorphism in patients with combined AH and GERD.Our research goal was to study frequency and variants of TNF gene G308A polymorphism relations with AH risk and AH phenotypic peculiarities in patients suffering from GERD.We examined 58 people who had AH (29 patients with isolated AH, average age being 53 [46; 62], and 29 patients with combined AH and GERD, average age being 56 [51; 59]). Patients from both groups were comparable in terms of sex, age, and examined factors of cardiovascular diseases risks. We applied allele-specific polymerase reaction with test systems produced by "Sintol" LLC (Moscow) to determine G308A (rs1800629) polymorphism of TNF gene. To assess relations between alleles and genotypes and disease risks, we calculated odds ratio (OR) with 95 % confidence interval (CI).We revealed a relation between G308A polymorph marker of TNF gene and systolic blood pressure and disorders in tolerance to dextrose among patients with comorbid AH and GERD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.